Comment on CFTC-2026-0331, CFTC-2026-0331-0001, Cameron, Zadeh

I am submitting this comment as an individual with a professional background in protein analysis and biological manufacturing. My interest in this rulemaking is narrow but direct: I believe nonprofit prediction markets can serve a meaningful function in scientific research integrity, and I think the Commission's framework should reflect that. The core function of a well-designed prediction market (aggregating distributed judgment into a public signal) maps onto a problem my field has struggled with for decades. A western blot can be run correctly, pass peer review, and still reflect a result that experienced researchers in the same subfield would privately doubt. That private doubt rarely surfaces in any form the broader scientific community can act on. The case of Marc Tessier-Lavigne, whose manipulated data shaped years of Alzheimer's research before a formal investigation concluded in 2023, is a public example of how long that gap between private skepticism and public signal can persist, and how much wasted effort and delayed treatment progress fills that gap. A prediction market populated by domain experts would have priced that uncertainty earlier and more transparently than the existing system of peer review and institutional reputation did. That is what I understand "disseminating pricing information" to mean in a research context. The price being discovered is not a commodity price. It is a credibility signal about a scientific claim, and that signal has real economic and human health consequences when it is absent or delayed. Nonprofit platforms built specifically to generate that signal for biomedical and policy-relevant questions are doing something categorically different from platforms built around contract volume and user engagement. The Commission's framework should be able to say that plainly. I understand that others are urging the Commission to formalize a distinct regulatory pathway for nonprofit research markets rather than continuing to administer it through discretionary staff letters. That distinction matters to me not as a regulatory abstraction but because the two kinds of markets are genuinely trying to do different things.